GlobeNewswire·Apr 14, 2026, 9:50 PM ET

Allogene Therapeutics Announces Pricing of Public Offering of Common Stock

Allogene Therapeutics announced an underwritten public offering of 87,500,000 common stock shares at $2.00 per share.
Gross proceeds from the offering are expected to be $175 million before deducting underwriting discounts, commissions, & estimated expenses.
The offering is expected to close on or about April 16, 2026, subject to customary closing conditions.
Underwriters have a 30-day option to purchase up to 13,125,000 additional shares at the public offering price.
Net proceeds will be used for general corporate purposes, including clinical trials, research & development, general & administrative expenses, & capital expenditures.
Goldman Sachs, Jefferies, & TD Cowen are acting as joint bookrunners, with Piper Sandler & William Blair also serving as joint bookrunners.
Baird & Canaccord Genuity are acting as lead managers, while TPG Capital BD is acting as co-manager.
The shares are being offered pursuant to a shelf registration statement declared effective on April 25, 2024.
A final prospectus supplement will be filed with the SEC & will be available on the SEC website.